Table 2.

VTEs according to treatment arm, histologic subtype and treatment phase

	Overall N = 300	Investigational Arm N = 149	Control Arm N = 151	Adeno-carcinoma N = 189	Squamous Cell Carcinoma N = 111
Overall (N)	8.7% (26b)	9.4% (14a)	7.9% (12)	11.1% (21a)	4.5% (5)
Preoperative (N = 300)	6.7% (20b)	8.0% (12a)	5.3% (8)	9% (17a)	2.7% (3)
Ind-CT	1.3% (4)	1.3% (2)	1.3% (2)	1.6% (3)	0.9% (1)
RCT	5.6% (16b)	7.1% (10a)	4.1% (6)	7.7% (14a)	1.9% (2)
Postoperative (N = 259)	3.1% (8)	3.1% (4)	3.1% (4)	3.5% (6)	2.3% (2)

^aOne of these patients had two simultaneous grade 3 VTEs in the RCT phase

^bTwo of these patients had two separate grade 3 VTEs at different time points